Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
•
SABCS 2024
In light of WSG-ADAPT HR+/HER2– trial at SABCS 2024 showing a 5 year iDFS benefit with neoadjuvant nab-paclitaxel over paclitaxel, will you change your practice?
Related Questions
What are your top takeaways in Radiation Oncology from SABCS 2024?
What are your top takeaways in Medical Oncology from SABCS 2024?
Would you offer adjuvant AC + pembrolizumab for a triple negative breast cancer patient whose tumor progressed on carboplatin + paclitaxel + pembrolizumab on KEYNOTE-522 and required urgent surgery (ypT3 ypN0)?
When do you recommend preoperative chemotherapy or hormonal therapy for ER+ breast cancer?
How do you treat high-risk inflammatory TNBC diagnosed in the first trimester of pregnancy who underwent surgery?
Is there evidence supporting the adjuvant use of neratinib in patients with high-risk, hormone receptor–positive, HER2-negative breast cancer that harbors an activating HER2 mutation?
Would you recommend adjuvant chemotherapy for older patients >75 years of age with T4b grade 2 HR+, HER2- mucinous carcinoma of the breast?
What is the appropriate approach to manage a patient with triple-negative, locally advanced breast cancer (LN+) who progresses on neoadjuvant chemo-immunotherapy (KEYNOTE-522 regimen)?
Would you offer neoadjuvant pembrolizumab to a TNBC patient with multiple pulmonary nodules and bilateral hilar adenopathy secondary to asymptomatic sarcoidosis (biopsy proven)?
Do you routinely check hormone levels to confirm postmenopausal status before adding aromatase inhibitors to OFS in premenopausal women with early breast cancer?
